INM - InMed Pharmaceuticals GAAP EPS of -$0.91 revenue of $0.47M

• InMed Pharmaceuticals press release ( NASDAQ: INM ): Q2 GAAP EPS of -$0.91.
• Revenue of $0.47M (+74.1% Y/Y).
• Approaches completion of enrollment for Ph 2 clinical trial in EB
• Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s.
• At December 31, 2022, the Company’s cash, cash equivalents and short-term investments were $11.5 million, which compares to $6.2 million at June 30, 2022.
• Shares +6.25% AH.

For further details see: